Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

NCT07349277 is registered in ClinicalTrials.gov with Ammar Jassim Abed as lead sponsor.

NCT NCT07349277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07349277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Lead sponsor
Ammar Jassim Abed
Phase
Observational
Overall status
Recruiting
Start date
October 10, 2025
Completion date
April 30, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational hypertension, hypertensive disorders of pregnancy, preeclampsia